News
StockStory.org on MSN15h
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price PressuresGlobal pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...
The U.S. and China, after trade talks in Geneva, agreed to cut tariffs on each other by 115 percentage points, for at least 90 days. Treasury Secretary Scott Bessent further added that talks on ...
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results